STUDY

A vitamin B3 pill cut new skin cancers by 23% in high-risk people

“A Phase 3 Randomized Trial of Nicotinamide for Skin-Cancer Chemoprevention.” Chen AC et al. New England Journal of Medicine. October 2015

Chen AC et al. · New England Journal of Medicine · October 2015

Randomized controlled trialActinic KeratosisSquamous Cell CarcinomaBasal Cell CarcinomaNiacinamide
The finding

In a 12-month trial of 386 people at high risk of skin cancer, 500 mg of nicotinamide (vitamin B3) twice a day lowered the rate of new nonmelanoma skin cancers by 23% compared with a placebo.

Type of study

Where this study sits on the evidence spectrum

Some kinds of studies are much more reliable than others. Studies further right do more to rule out chance and bias.

Weaker evidenceStronger evidence
Lab or animal studyCase reportCase seriesCohort studyRandomized trialMeta-analysis
Randomized and double-blind. A random process decided who got nicotinamide and who got a placebo, and neither the patients nor the doctors knew which one they had. That keeps expectations from skewing the results.
At a glance

Who was studied and for how long

People
386
Split 1 to 1 into two groups
Length
12 months
Skin checks every 3 months for 18 months
Who
High-risk skin
At least 2 skin cancers in the past 5 years
Compared
Nicotinamide vs placebo
A vitamin B3 pill vs a dummy pill
Dose
500 mg
Twice a day, by mouth
Where
Sydney, multicenter
More than one clinic
What they did

How the study worked

386 peoplehigh skin cancer riskRANDOMSPLITNicotinamideHalf500 mg twice dailyPlaceboHalfdummy pillMEASURED ATMonth 12new skin cancers386 peoplehigh skin cancer riskRANDOMSPLITNicotinamideHalf · 500 mg twice dailyPlaceboHalf · dummy pillMEASURED ATMonth 12new skin cancers
1. Split at random386 people who had had at least two skin cancers in the past 5 years were randomly put in one of two groups.
2. Pill or placeboOne group took 500 mg of nicotinamide twice a day. The other took a placebo. Both did this for 12 months.
3. Skin checksDermatologists checked everyone every 3 months for 18 months and counted new skin cancers.
What they found

The results

NicotinamidePlacebo

New skin cancers (main result)

Change in new nonmelanoma skin cancers at 12 months, compared with placebo

Nicotinamide
−23%
Placebo
0%
Difference unlikely to be chance (p = 0.02)

Squamous cell cancers

Change in new squamous cell cancers, compared with placebo

Nicotinamide
−30%
Placebo
0%
Borderline (p = 0.05)

Basal cell cancers

Change in new basal cell cancers, compared with placebo

Nicotinamide
−20%
Placebo
0%
Difference could be chance (p = 0.12)

Sun-damaged spots (actinic keratoses)

Change in the number of spots at 12 months, compared with placebo

Nicotinamide
−13%
Placebo
0%
Difference unlikely to be chance (p = 0.001)
Each bar shows how much lower the rate was with nicotinamide than with placebo. For all skin cancers together, the drop of 23% was unlikely to be chance. For basal cell cancers alone, the gap was small enough that it could be chance. The benefit did not continue after people stopped taking nicotinamide.
Who paid for it

Funding and conflicts of interest

Funded by the National Health and Medical Research Council.

How much to trust it

Strengths and limits

Strengths

  • Randomized, double-blind and placebo-controlled, a strong design
  • Dermatologists checked everyone at set visits
  • People were followed for 6 months after treatment ended

Limits

  • Only people at high risk: at least 2 skin cancers in the past 5 years
  • Tested a pill, not a skin cream or serum
  • No benefit was seen after people stopped taking it
  • One trial: 12 months of treatment, so long-term effects are not known
Higher confidence. A well-run trial in a high-risk group. It does not show the same benefit for people at average risk.
What it means for you

The takeaway

Ask your dermatologist

If you have had several skin cancers, ask your dermatologist about oral nicotinamide. In this trial it lowered new nonmelanoma skin cancers, but only while people were taking it.

This study tested a pill. It did not test skin creams or serums, and it does not replace sun protection or regular skin checks.

Pages that cite this study

Read more on Dermapedia

Terms in this study

Words worth knowing

Nonmelanoma skin cancer

The two most common skin cancers, basal cell and squamous cell carcinoma. Both are caused mainly by UV radiation from the sun.

Actinic keratosis

A rough, scaly spot caused by sun damage. Some can turn into skin cancer.

Placebo

A dummy pill with no active ingredient, used for comparison.

Nicotinamide

Another name for niacinamide, a form of vitamin B3.

Original source

Chen AC, Martin AJ, Choy B, Fernández-Peñas P, Dalziell RA, McKenzie CA, Scolyer RA, Dhillon HM, Vardy JL, Kricker A, St George G, Chinniah N, Halliday GM, Damian DL. A Phase 3 Randomized Trial of Nicotinamide for Skin-Cancer Chemoprevention. N Engl J Med. 2015;373(17):1618–1626.

PMID 26488693